4th Quarter - Amendment

NOVARTIS for NOVARTIS

Firm
Client
Income
—
Expenses
$1,760,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report Jan 20, 2023 $880,000 Replaced
4th Quarter - Amendment (this page) Oct 20, 2023 $1,760,000 Yes

What was lobbied

8 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Advanced Research Projects Agency for Health (ARPA-H) Biosimilars Fiscal year 2023 Appropriations H.R. 6833 - Continuing Appropriations H.R.1, For the People Act of 2021 H.R.1319, American Rescue Plan Act of 2021 H.R.2471, Consolidated Appropriations Act for FY 2022 H.R.5376, Inflation Reduction Act Importation National Defense Authorization Act FY 2023 Prescription Drug User Fee Act (PDUFA) VII Value of Medicine

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); SENATE; White House Office

Bills named: H.R. 5376 (117th), H.R. 1 (117th), H.R. 2471 (117th), H.R. 1319 (117th), H.R. 6833 (117th)

Copyright/Patent/Trademark CPT

Antitrust Legislation Bayh-Dole Act Biopharmaceutical Intellectual Property Biosimilars BPCIA Compulsory licenses Data Exclusivity Intellectual Property Issues in Response to coronavirus Inter Parties Review at PTO Patent Litigation Reform and Issues Related to Post Grant Proceedings at PTO Patents S.1435, Affordable Prescriptions for Patients Act of 2021 S.225, Competition and Antitrust Law Enforcement Reform Act Section 101 H.R. 2883, the Stop Stalling Access to Affordable Medications H.R. 2891, the Preserve Access to Affordable Generics and Biosimilars Act H.R. 2873, the Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 2884, the Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act WTO TRIPS Waiver March in rights

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); SENATE

Bills named: S. 225 (117th), H.R. 2891 (117th), S. 1435 (117th), H.R. 2884 (117th), H.R. 2883 (117th), H.R. 2873 (117th)

Health Issues HCR

21st Century Cures Act 2.0 340B Drug Discount Program Advanced Research Projects Agency for Health (ARPA-H) Biosimilar approval and reimbursement policy issues BLOCKING Act Buy American and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients Cell, gene and radioligand therapies Co-pay accumulator programs COVID-19 Diversity in Clinical Trials Drug cost and pricing policy issues Drug Importation and counterfeiting policy issues Drug shortages policy issues Drug vial size policy issues FDA modernization policy issues Foreign manufacturing policy issues FY 2023 Appropriations H.R.2471, Consolidated Appropriations Act for FY 2022 H.R.3, Elijah E. Cummings Lower Drug Costs Now Act H.R.5463, Drug Pricing Transparency and Accountability Act H.R. 5260, Reduced Costs and Continued Cures Act H.R. 4811, Medicare Negotiation and Competitive Licensing Act of 2021 Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 Medicaid Generics Penalty Fix Medicaid Payment Reform H.R. 5376 - Inflation Reduction Act H.R. 5801 - HELP Co-pays Act H.R. 7389 - MVP Act H.R. 6584 - DEPICT Act Notice of Benefit Payment Parameters (NBPP) Orphan Drugs Outcomes based contracting/value based arrangements Part B Home Infusion Patient assistance program policy issues PDUFA, BSUFA, GDUFA H.R 7667 - Food and Drug Amendments Act of 2022 S.4348 - FDASLA Act of 2022 Pharmaceutical quality Pharmaceutical supply chain H.R.5388/S.2740 PREPARE ACT of 2021 (API stockpiling) Priority Review Voucher (PRV) Regulatory efficiencies policy issues S.1427, HR 2869 - Increasing Access to Biosimilars Act of 2021 Transparency policy issues Vaccines White House National Biodefense Strategy H.R. 5416, The Give Kids a Chance Act S. 2837 - 340B Accountability Act 2021 Pharmacy benefit manager policy issues Cancer Moonshot

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); White House Office; SENATE; Office of Management & Budget (OMB); Food & Drug Administration (FDA)

Bills named: H.R. 5463 (117th), H.R. 2869 (117th), H.R. 4811 (117th), H.R. 7667 (117th), S. 2837 (117th), H.R. 5801 (117th), S. 1427 (117th), H.R. 7389 (117th), H.R. 6584 (117th), H.R. 2471 (117th), H.R. 5260 (117th), H.R. 5376 (117th), S. 4348 (117th), S. 2740 (117th), H.R. 3 (117th), H.R. 5388 (117th), H.R. 5416 (117th)

Medicare/Medicaid MMM

Anti-Kickback Statute policy issues ASP reporting policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues Drug Pricing Drug wastage rebates policy issues Innovative Pharmaceuticals (including cell, gene and radioligand therapies), Biosimilars and Generics Medicaid Medicare Part D Negotiations Medicare Part D Re-design and out of pocket cap Medicaid rebates and waiver policy issues Medicare Part A, B and D Patient Cost-Sharing and Smoothing Reimbursement for cell therapy products Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals Transparency policy issues H.R. 5376 - Inflation Reduction Act Implementation

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); White House Office; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: H.R. 5376 (117th)

Taxation/Internal Revenue Code TAX

Administrations FY 2023 Revenue Proposals Orphan Drug Tax Pharmaceutical supply chain incentives R&D Amortization Restrict deductions of excessive interest of members of financial reporting groups for disproportionate borrowing in the United States (Sec. 163(n) & 163(o)) Tax Treaties Thin Capitalization Rules 163(j) U.S. Corporate Tax

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
JOSEPH MCGOWAN —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Trade (domestic/foreign) TRD

Access to Medicines Issues Biopharmaceutical Innovation Policies China Agreement Free Trade Agreements - Intellectual Property and Transparency Provisions Global Health Issues India, China and Canada IP and Market Access Issues International Market Access and Intellectual Property Issues Pharmaceutical Supply Chain Pricing and reimbursement Regulatory Cooperation Tariffs Trade Policy US Swiss Trade Agreement USTR Special 301 Report/National Trade Estimate WTO IP Waiver

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: White House Office; Health & Human Services, Dept of (HHS); U.S. Agency for International Development (USAID); SENATE; HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); U.S. Trade Representative (USTR); State, Dept of (DOS)

Veterans VET

Health care collaboration opportunities

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
LEO A FARBER —
JOSEPH MCGOWAN —
COURTNEY PIRON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Veterans Affairs, Dept of (VA)

Labor Issues/Antitrust/Workplace LBR

Anti-Trust Reform The Competition and Antitrust Law Enforcement Reform Act (S.225)

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
LEO A FARBER —
JOSEPH MCGOWAN —
COURTNEY PIRON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 225 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.